clinical

Articles

Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.

AAO 2020: Fingolimod for MS offers disease control with no development of uveitis

Videos

Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.

AAO 2020: Study confirms Phase III results for uveitis treatment

Chronic cases can be difficult for retina specialists; treatment is satisfying.

Noninfectious uveitis: Meeting the challenge

Cheryl Guttman Krader is a contributor to Dermatology Times, Ophthalmology Times, and Urology Times.

Look for clues to simplify anterior uveitis diagnosis

Inhibition plays role in autoimmune-based inflammation; has unique mechanism of action

Ongoing study evaluates sirolimus as therapeutic option for uveitis 

One biologic response modifier has indication for uveitis; several in development to gain FDA approval

Biologics may offer systemic therapy option for uveitis  

Quiescence, steroid-free quiescence achieved in VISUAL III trial

Adalimumab efficacious for uveitis regardless of disease duration

FA implant effective in lowering recurrence rates through available 6, 12 months of follow-up

Sustained-release corticosteroid expands armamentarium for uveitis 

Improvement in visual acuity, central retinal thickness, vitreous haze reported at 6 months

Tocilizumab effective for managing posterior segment inflammation

Intravitreal triamcinolone acetonide, dexamethasone implant superior for regional treatment of disorder

Managing uveitic macular edema

Understanding etiology crucial for appropriate uveitic treatment

IL-6 inhibition shows promise as treatment for non-infectious uveitis

Novel local corticosteroid therapy shows positive efficacy signals, favorable safety profile says Rahul Khurana, MD.

Data promising in uveitic macular edema pivotal trial 

Adalimumab therapy safe, effective in real-world, open-label uveitis study

Uveitis does not have to be vexing. Here are some basic principles to make it easier for ophthalmologists to identify the disorder, says James Philip Dunn Jr., MD

Pearls for better uveitis workups

Intravitreal sirolimus 400 mcg (Ospiria, Santen) demonstrated positive results in pivotal trials investigating it as a treatment for non-infectious uveitis of the posterior segment. A New Drug Application is under FDA review.

Sirolimus shows promise for posterior segment non-infectious uveitis

Local therapy plays a significant role in the treatment of uveitis, either as monotherapy or in combination therapy. Alongside a number of pharmacotherapeutic agents, new products and technologies are in development that could expand clinicians’ options and improve outcomes.

New and different therapies emerging through uveitis pipeline

Results from the Study Assessing double-masKed Uveitis tREAtrement (SAKURA) program support the efficacy and safety of intravitreal sirolimus 440 mcg (Opsiria, Santen) for treating noninfectious uveitis of the posterior segment, said Pauline T. Merrill, MD.

SAKURA program reinforces efficacy, safety of intravitreal sirolimus

Adalimumab promising in treating JIA-associated uveitis, study finds

Adalimumab (Humira, AbbVie), an immunosuppressive biologic therapy, improves the symptoms of noninfectious active uveitis, but causes some adverse events and does not cure the disease, researchers say.